Effect of hyperimmune bovine milk & colostrum in the healing process of COVID-19 patients

Comparison of the Effectiveness of COVID-19 specific antibody in hyper-immune bovine milk & colostrum with ordinary bovine milk & colostrum on reducing the need for hospitalization and improving clinical symptoms of patients with COVID-19 that are taken care of in home.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200927048849N3

Enrollment

600

Registered

2021-03-17

Start date

2021-03-20

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19 viral pneumonia. Pneumonia due to SARS-associated coronavirus

Interventions

Intervention 1: Intervention group: Referred COVID-19 patients to clinic of Alzahra hospital after explaining the study and obtaining consent the will be given twice a day, morning and evening 150 cc

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Infected patients of COVID-19 based on positive Polymerase Chain Reaction test Lack of hospitalization indication based on country protocol O2 Saturation more than 93% on the first visit Respiratory rate more than 24 on the first visit Age more than 18 years old Filling and signing of consent form A maximum of 10 days have elapsed since the onset of disease symptoms

Exclusion criteria

Exclusion criteria: Patients with immunodeficiency based on biography Lactose intolerance based on biography Uncontrollable vomiting Using antiviral drugs Pregnancy Failure to fill out the consent form Receiving immunosuppressive drugs

Design outcomes

Primary

Measure	Time frame
Need of Hospitalization during the next 14 days. Timepoint: 14 days after using the milk. Method of measurement: By phone call.;Need to go to the emergency room during 14 days. Timepoint: 14 days after using the milk. Method of measurement: By phone call.;No fever and appearance of it. Timepoint: In days of 3, 5, 7, 10 and 14 after beginning the treatment. Method of measurement: By phone call.;No cough and appearance of it. Timepoint: In days of 3, 5, 7, 10 and 14 after beginning the treatment. Method of measurement: By phone call.;No shortness of breath and appearance of it. Timepoint: In days of 3, 5, 7, 10, 14 after beginning the treatment. Method of measurement: By phone call.;No muscular pain and appearance of it. Timepoint: In days of 3, 5, 7, 10, 14 after beginning the treatment. Method of measurement: By phone call.;Mortality rate during 28 days after beginning of the disease. Timepoint: 28 days after beginning of disease. Method of measurement: By phone call.;ICU need during 28 days after beginning the disease. Timepoint: 28 days after beginning of disease. Method of measurement: By phone call.	—

Measure

Time frame

Need of Hospitalization during the next 14 days. Timepoint: 14 days after using the milk. Method of measurement: By phone call.;Need to go to the emergency room during 14 days. Timepoint: 14 days after using the milk. Method of measurement: By phone call.;No fever and appearance of it. Timepoint: In days of 3, 5, 7, 10 and 14 after beginning the treatment. Method of measurement: By phone call.;No cough and appearance of it. Timepoint: In days of 3, 5, 7, 10 and 14 after beginning the treatment. Method of measurement: By phone call.;No shortness of breath and appearance of it. Timepoint: In days of 3, 5, 7, 10, 14 after beginning the treatment. Method of measurement: By phone call.;No muscular pain and appearance of it. Timepoint: In days of 3, 5, 7, 10, 14 after beginning the treatment. Method of measurement: By phone call.;Mortality rate during 28 days after beginning of the disease. Timepoint: 28 days after beginning of disease. Method of measurement: By phone call.;ICU need during 28 days after beginning the disease. Timepoint: 28 days after beginning of disease. Method of measurement: By phone call.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHassan Niliahmadabadi

Virus research center of Isfahan university

nili@shirazu.ac.ir+98 31 3261 6334

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026